Antimicrobial Regimens Prescribed by Canadian Physicians for Chemotherapy-Induced Febrile Neutropenic Episodes

Simple item page
dc.contributor.authorLaverdière, Michel
dc.contributor.authorBow, Eric J
dc.contributor.authorRotstein, Coleman
dc.contributor.authorIoannou, Stratis
dc.contributor.authorCarr, Danielle
dc.contributor.authorMoghaddam, Narguess
dc.contributor.authorthe Canadian Fluconazole Study Group,
dc.date.accessioned2016-06-09T14:42:23Z
dc.date.available2016-06-09T14:42:23Z
dc.date.issued1999-1-1
dc.date.updated2016-06-07T07:02:02Z
dc.description.abstractOBJECTIVE: To study the antimicrobial management of cancer patients with chemotherapy-induced neutropenia by Canadian physicians.SETTING: A cohort of 274 cancer patients with severe neutropenia (ie, less than 0.5×109 neutrophils/L) who participated in a prospective double-blind, placebo controlled study on antifungal prophylaxis conducted in 14 Canadian university-affiliated centres. Antifungal prophylaxis (oral fluconazole 400 mg daily) was administered to 153 of 274 (56%) patients.RESULTS: Antibacterial prophylaxis with a quinolone was given to 87 patients (32%) at the onset of chemotherapy whereas trimethoprim/sulphamethoxazole was given to 56 (20%) patients. Fever (ie, 38°C or over) occurred in 216 (79%) patients after a median duration of neutropenia of four days (range one to 31 days). Empirical antibacterial antibiotics were administered in 214 febrile patients. In 164 (77%) patients antibiotics were started during the first 24 h of fever. Monotherapy with a third generation cephalosporin and duotherapy with a antipseudomonal beta-lactam and an aminoglycoside were prescribed in 69 (32%) and 61 (28%) of the febrile patients, respectively. Inclusion of vancomycin in the initial empirical regimen was noted in 32 (15%) patients. Modifications of the initial regimen occurred in 187 (87%) patients after a median of five days (range one to 28 days). Empirical systemic amphotericin B was added after a median duration of nine days (range one to 34 days) of the empirical antibacterial regimen.CONCLUSIONS: Overall, the antimicrobial management of cancer patients with chemotherapy-induced neutropenia by Canadian physicians follows the current guidelines promulgated by the Infectious Diseases Society of America.
dc.description.versionPeer Reviewed
dc.identifier.citationMichel Laverdière, Eric J Bow, Coleman Rotstein, et al., “Antimicrobial Regimens Prescribed by Canadian Physicians for Chemotherapy-Induced Febrile Neutropenic Episodes,” Canadian Journal of Infectious Diseases, vol. 10, no. 5, pp. 353-357, 1999. doi:10.1155/1999/721790
dc.identifier.urihttp://dx.doi.org/10.1155/1999/721790
dc.identifier.urihttp://hdl.handle.net/1993/31450
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderCopyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleAntimicrobial Regimens Prescribed by Canadian Physicians for Chemotherapy-Induced Febrile Neutropenic Episodes
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
CJIDMM.1999.721790.xml
Size:
13.92 KB
Format:
Extensible Markup Language
Description:
Download
Thumbnail Image
Name:
CJIDMM.1999.721790.pdf
Size:
128.16 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works